Navigation Links
Neurocrine Advances VMAT2 Inhibitor Program
Date:12/21/2009

SAN DIEGO, Dec. 21 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced their highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor, NBI-98854, will be advanced in clinical development.

The first trial in human subjects, NBI-98854-0801, was a single ascending dose trial in healthy male volunteers conducted in Canada under an approved Clinical Trial Application (CTA) with Health Canada. Preliminary data have now been reviewed; NBI-98854 was generally safe and well tolerated. There were no Serious Adverse Events, clinically significant drug-related laboratory abnormalities or clinically significant ECG findings. More critically, the characteristics of the compound met the pre-specified pharmacokinetic requirements: dose proportionality, low maximum concentration (Cmax) with adequate area-under-curve (AUC) for drug exposure, low variability, and a half-life which supports once per day dosing.

"The results of this first clinical trial in our VMAT2 inhibitor are exactly what we were seeking," said Chris O'Brien, Chief Medical Officer of Neurocrine Biosciences. "We will now move NBI-98854 into a multiple repeated dose Phase 1 study and begin preparation for Phase 2 proof of concept trial to be initiated later in 2010."

VMAT2 is a protein concentrated in the human brain that is primarily responsible for re-packaging and transporting monoamines (dopamine, norepinephrine, serotonin, and histamine) among nerve cells. NBI-98854, developed in the Neurocrine laboratories, is a novel highly selective VMAT2 inhibitor that is effective in regulating the levels of dopamine release during nerve communication, while at the same time having minimal impact on the other monoamines thereby reducing the likelihood of "off target" side effects. NBI-98854 is designed to provide low, susta
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
2. Neurocrine Biosciences Reports First Quarter 2008 Results
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
5. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
6. Neurocrine Biosciences Presents Elagolix Data
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
8. Neurocrine Biosciences Reports Third Quarter 2009 Results
9. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Calif. , July 10, 2014  Breg, ... and services, has launched the FreeRunner™ knee brace ... who suffer from patella mal-tracking return to active ... differently than other braces, providing support when patients ... normally when they don,t. Patellofemoral issues ...
(Date:7/10/2014)... July 10, 2014  BC Technical, the largest nationwide, ... America , Inc., a leading provider of Siemens Nuclear ... long-term agreement naming BC Technical as the authorized provider ... MiE and BC Technical announced today that the ... BC Technical as the service and systems provider for ...
(Date:7/10/2014)... , July 10, 2014   LabStyle ... Management Solution, today announced the appointment of Professor ... member of its Board of Directors. ... and business experience to LabStyle as an entrepreneur, ... legal and corporate governance expert. He currently serves ...
Breaking Medicine Technology:Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4
... Mass., Feb. 17, 2011 Echo Therapeutics, Inc. (OTC ... the Symphony™ tCGM System as a non-invasive, wireless, transdermal ... System for transdermal drug delivery, announced that development of ... schedule.  The company said that the system will be ...
... Technologies,™ Inc. today announced it has enrolled the first patient ... irolimus and a bioabsorbable p OL ymer for the treatment ... in the native coronary arteries) clinical trial.  Stefan Verheye, M.D., ... in the study. This clinical investigation is being conducted to ...
Cached Medicine Technology:Echo Therapeutics Reports Symphony™ tCGM System Ahead of Schedule 2Echo Therapeutics Reports Symphony™ tCGM System Ahead of Schedule 3Micell Technologies Enrolls First Patient in CE Mark DESSOLVE II Study of MiStent™ Drug-Eluting Coronary Stent (DES) 2Micell Technologies Enrolls First Patient in CE Mark DESSOLVE II Study of MiStent™ Drug-Eluting Coronary Stent (DES) 3Micell Technologies Enrolls First Patient in CE Mark DESSOLVE II Study of MiStent™ Drug-Eluting Coronary Stent (DES) 4
(Date:7/11/2014)... According to new report "C4ISR Market (2014 - ... a CAGR of 2.28% to reach $93.04 billion ... and 76 figures spread through 185 pages and ... , Early buyers will receive 10% customization on ... provides market analysis of the global C4ISR Market ...
(Date:7/11/2014)... the number of deer in an area can lower ... infections among people, new research indicates. "Our study ... human interactions with deer, infected nymphal ticks and human ... White-tailed deer are the primary host for adult blacklegged ... study included nearly all the permanent residents of a ...
(Date:7/11/2014)... Microbiology testing is a highly dynamic and ... is expected to pose the biggest challenge to suppliers ... growth to the ongoing spread of AIDS – still ... major factor leading to the upsurge of opportunistic infections, ... broader availability of immunosuppressants, among others. , Market ...
(Date:7/11/2014)... July 11, 2014 Datalogic brings a ... improving sanitation hospital wide. With their new Gryphon ... of disease, like the devastating MRSA, which claimed 5,500 ... GD4400-HC 2D and the Gryphon GM4400-HC 2D ... and can even read barcodes off of troublesome LCD ...
(Date:7/11/2014)... FRIDAY, July 11, 2014 (HealthDay News) -- Children ... greater risk for complications and potentially even death ... a new study. However, the Johns Hopkins ... "miniscule." The researchers analyzed data on nearly ... United States underwent over a 22-year period. ...
Breaking Medicine News(10 mins):Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 3Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 4Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2
... PITTSBURGH, April 29 Mylan Inc. (NYSE: ... Michael J. Monroe as senior vice,president - ... of the company,s senior,leadership team. In this ... and employee communications; corporate,branding/marketing; corporate media relations; ...
... also contributed to early dropout rate, study says , , ... problem drug users, and those not currently injecting drugs, ... a British study finds. , University of Kent and ... drug users in treatment programs and found that 25 ...
... Society finds cancer survivors who follow health behavior recommendations ... getting adequate exercisehave higher health-related quality of life (HRQoL) ... The study, which appears in the May issue of ... have low rates of smoking, but few are meeting ...
... factor most commonly used to predict whether an extremely ... that can help predict a preemies outcome have been ... Network, of which Yale is a member. , ... and whether the mother was given antenatal steroid mediation ...
... New York, NY -- A JDRF collaboration between Johns ... for the treatment of diabetic eye disease has performed ... using laser surgery. , These findings, representing the ... by The Johns Hopkins University, were presented Monday at ...
... Layoffs and Loss of Healthcare Services, PRINCETON, N.J., ... drives and longer waits for care.,Those are among the ... state,s $300 million in proposed healthcare cuts are approved., ... healthcare leaders from across,the state met with Gov. Jon ...
Cached Medicine News:Health News:Mylan Appoints Michael J. Monroe Senior Vice President for Global Public Affairs 2Health News:Youngest Drug Users Most Likely to Leave Treatment Programs 2Health News:Cancer survivors who practice healthy habits have higher quality of life 2Health News:Factors affecting survival, disability of extremely premature infants identified 2Health News:Promising early evidence of the superior benefits of drug therapy for diabetic eye disease 2Health News:Hospital CEOs Meet with Governor on Budget Cuts 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: